Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743

Lung, Respiratory and Thoracic Cancer

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

J Thorac Oncol

Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS

doi: 10.1016/j.jtho.2025.05.019

Lung, Respiratory and Thoracic Cancer

Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

Lung Cancer

Ono S, Taniguchi H, Kuroda K, Hashimoto T, Okada A, Goto Y, Kitai H, Nakamura Y, Ogusu S, Hase T, Ota T, Ebi N, Furugen M, Harada T, Kinoshita Y, Mizoguchi T, Nakatomi K, Soejima Y, Yamada T, Takemoto S, Mukae H

doi: 10.1016/j.lungcan.2025.108709

Gastrointestinal Cancer

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

Ann Oncol

Janjigian YY, Shitara K, Ajani JA, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, McCraith S, Hu N, Lei M, Zhang J, Moehler M

doi: 10.1016/j.annonc.2026.02.003

Lung, Respiratory and Thoracic Cancer

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial

J Thorac Oncol

Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC

doi: 10.1016/j.jtho.2026.103609

Lung, Respiratory and Thoracic Cancer

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Lung Cancer

Shah R, Buchmeier EL, Kopp HG, Christoph DC, Griesinger F, Reck M, Hoffknecht P, Kuon J, Frost N, Grohé C, Faehling M, Luan J, Roeper J, Chesi P, Blasi M, Kimmich M, Olchers T, Bischoff H, Klotz LV, Chung I, Christopoulos P, Thomas M

doi: 10.1016/j.lungcan.2025.108702

Lung, Respiratory and Thoracic Cancer

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

Lancet Oncol

Zhou C, Wang Z, Sun M, Cao L, Ma Z, Wu R, Yu Y, Yao W, Sun S, Chen J, Zhuang W, Cui J, Chen X, Lu Y, Shen H, Hu C, Liu J, Liu Y, Wang M, Li X, Sun P, Shu Y, Zhou J, Li J, Gu K, Wang C, Zhao H, Zhang Y, Liu C, Yang H, Zhang X, Ma R, Li L, Liang L, Li M, Wang J, Wang Q, Wang B, Dai H, Shi Q, Yang J

doi: 10.1016/S1470-2045(25)00198-6

ESMO 2025

Gastrointestinal Cancer

CheckMate 8HW: Nivolumab plus ipilimumab provides clinically meaningful benefits over nivolumab alone in MSI-H/dMMR-positive mCRC

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Lung Cancer

Paz-Ares L, Veillon R, Majem M, Zhou C, Tang KJ, Kim SW, Richardson G, Girard N, Sanborn RE, Mansfield AS, Park K, Schuchard J, Diels J, Sermon J, Bhattacharya A, Lorenzini P, Wortman-Vayn H, Knoblauch RE, Agrawal T, Baig M, Ono A, Sabari JK

doi: 10.1016/j.lungcan.2025.108788

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Related content

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649

Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial

First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial

CheckMate 8HW: Nivolumab plus ipilimumab provides clinically meaningful benefits over nivolumab alone in MSI-H/dMMR-positive mCRC

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States